• In late April 2026, Oruka Therapeutics reported positive interim Phase 2a data for its psoriasis drug candidate ORKA-001 and secured a US$700.35 million follow-on equity offering alongside a global exclusive collaboration and license agreement with Halozyme Therapeutics to apply Hypercon™ delivery technology to ORKA-001.
• Together, the strong clinical efficacy signals, sizable capital raise, and Halozyme partnership position ORKA-001 as a potentially more convenient biologic option in psoriasis and related inflammatory diseases.
• Next, we'll examine how the Halozyme Hypercon collaboration and encouraging ORKA-001 trial data shape Oruka Therapeutics' broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Oruka Therapeutics' Investment Narrative?

To own Oruka here, you essentially have to believe that ORKA-001 and ORKA-002 can justify a rich, pre-revenue valuation by evolving into meaningful dermatology franchises, backed by differentiated dosing profiles. The recent Phase 2a psoriasis data and the Halozyme Hypercon collaboration strengthen that narrative, suggesting ORKA-001 could become a more convenient biologic option if later-stage trials confirm these early signals. The US$700.35 million follow-on raise meaningfully reduces near-term funding risk and provides flexibility to push both ORKA-001 and ORKA-002 through expensive mid-stage programs, although it also adds to a pattern of dilution. In the short term, the key catalysts now skew toward longer-term readouts from EVERLAST-A and EVERLAST-B, while nearer issues include the June 2026 lock-up expiry, trial execution risk, and the possibility that enthusiasm for the Phase 2a data is already reflected in the share price after a very large one-year return.

However, investors should not overlook the execution and dilution risks now sitting in the background. Upon reviewing our latest valuation report, Oruka Therapeutics' share price might be too optimistic.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community range widely, from about US$14.22 to US$142.17, underscoring how differently people are weighing Oruka’s mid-stage trial success, heavy losses and recent US$700.35 million raise. With such a spread in expectations, it becomes even more important to consider how dependent the story is on ORKA-001 delivering clean, confirmatory data over the next few years.

Explore 2 other fair value estimates on Oruka Therapeutics - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oruka Therapeutics research is our analysis highlighting 5 important warning signs that could impact your investment decision.
• Our free Oruka Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oruka Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.